KRAS and NRAS Wild-type Colorectal Cancer Clinical Trial
Official title:
Combination Study of Panitumumab and Regorafenib in Advanced or Metastatic KRAS and NRAS Wild Type Colorectal Cancers
Evaluate the safety of regorafenib and panitumumab
n/a
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment